Changes of coagulation parameters during high altitude expedition

Swiss Medical Weekly

Volumn 140, Issue 7-8, 2010, Pages 111-117

  Hefti, Jacqueline Pichler ^a   Risch, Lorenz ^b   Hefti, Urs ^a   Scharrer, Inge ^c   Risch, Gert ^d   Merz, Tobias M ^e   Turk, Alex ^f   Bosch, Martina M ^g   Barthelmess, Daniel ^e   Schoch, Otto ^h   Maggiorini, Marco ⁱ   Huber, Andreas R ^a  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b Academic Teaching Hospital   (Austria)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d LMZ Risch Laboratories   (Liechtenstein)

^e UNIVERSITY OF BERN   (Switzerland)

^f Hohenklinik Wald   (Switzerland)

^g Höhenklinik Wald ^*  (Switzerland)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

ADAMTS 13; APC R; Coagulation; High altitude expedition; Von Willebrandt factor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; D DIMER; NATRIURETIC PEPTIDE TYPE C; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ALTITUDE; ARTICLE; BLOOD CLOTTING; CHINA; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPOBARISM; HYPOXIA; MALE; MOUNTAINEERING; NORMAL HUMAN; PROTHROMBIN TIME; SCORING SYSTEM;

EID: 77249119718     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Basnyat B, Murdoch DR. High altitude illness. Lancet. 2003; 361:1967-74.
2. Hackett PH, Roach RC. High altitude illness. N Engl J Med. 2001;345:107-14.
3. Schneider M, Bernasch D, Weymann J, Holle R, Bartsch P. Acute mountain sickness: influence of susceptibility, preexposure and ascent rate. Med Sci Sports Exerc. 2002;34:1886-91.
4. Roach RC, Bartsch P, Oelz O, Hackett PH. Lake Louise AMS Scoring Consensus Committee 1993. The Lake Louise acute mountain sickness scoring system. In: J.R Sutton, C.S. Houston, G. Coates (eds) Hypoxia and Molecular Medicine, p.p. 272-4. Charles S. Houston, Burlington, VT.
5. Swenson E, Maggiorini M, Mongovin St, Gibbs J, Greve I, Mairbäurl H, et al. Pathogenesis of High Altitude Pulmonary Edema: Inflammation is not an etiologic factor. JAMA. 2002;287:2228-35.
6. West JB, Colice GL, Lee Y-J, Namba Y, Kurdak SS, Fu Z, et al. Pathogenesis of High-Altitude Pulmonary Oedema: direct evidence of stress failure of pulmonary capillaries. Eur Respir J. 1995;8:523-9.
7. Dickinson JD, Heath D, Gosney J, Williams D. Altitude related deaths in seven trekkers in the Himalayas. Thorax. 1983;38:646-56.
8. Manneci PM, Gringeri A, Peyvandi F, Di Paobentorinio T, Mariani G. Short term exposure to high altitude causes coagulation activation and inhibits fibrinolysis. Thromb Haemost. 2002;87:342-3.
9. Torgovidey R, Azarian B, Grossman A, Eliyahn U, Goldstein L. Sinus vein thrombosis following exposure to simulated high altitude. Aviat Space Environ. Med. 2005;76:144-6.
10. Singh I, Chohan IS. Blood coagulation changes at high altitude predisposing to pulmonary hypertension. Br Heart J. 1997;34:611-7.
11. Bärtsch P, Haeberli A, Franciolli M, Kruithof EKO, Straub PW. Coagulation and fibrinolysis in acute mountain sickness and beginning pulmonary oedema. J Appl Physiol. 1989;66:2136-44.
12. Andrew M, O'Brodovich H, Sutton J. Operation Everest II: coagulation system during prolonged decompression to 282 Torr. J Applied Physiol. 1987;63(3):1262-7.
13. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 112(1):11-8.
14. Furlan M. Proteolytic cleavage of von Willebrand factor by ADAMTS-13 prevents uninvited clumping of blood platelets. J Thromb Haemost. 2004;2(9):1505-9.
15. Lopes AA, Maeda NY, Bydlowski SP. Abnormalities in circulating von Willebrand factor and survival in pulmonary hypertension. Am J Med. 1998;105:21.
16. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100(2):710-3.
17. Tsai HM. Molecular mechanisms in thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 2004;30(5):549-57.
18. Caramurú LH, de PS Soares R, Maeda NY, Lopes AA. Hypoxia and altered platelet behaviour influence Von Willebrand factor multimeric composition in secondary pulmonary hypertension. Clin Appl Thrombosis/ Hemostasis. 2003;9:252-8.
19. Pichler J, Risch L, Hefti U, Merz TM, Turk AJ, Bloch KE, et al. Glomerular filtration rate estimates decrease during high altitude expedition but increase with Lake Louise acute mountain sickness scores. Acta Physiol (Oxf). 2008;192:443-50.
20. Roach RC, Bärtsch P, Oelz O, Hackett PH, Lake Louise AMS. Scoring Consensus Committee. 1993. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Houston CS, Coates G, eds. Hypoxia and molecular medicine. pp 272-4, Charles S. Houston, Burlington, Vt.
21. Risch L, Monn A, Lüthy R, Honegger H, Huber AR. The predictive characteristics of D-Dimer testing in outpatients with suspected venous thromboembolism: a Bayesian approach. Clin Chim Acta. 2004;345:79-87.
22. Prickett TC, Yandle TG, Nicholls MG, Espiner EA, Richards AM. Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochem Biophys Res Commun. 2001;286:513-7.
23. Böhm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol. 2002;81:430-5.
24. Cushman M, Folsom AR, Wang L, Aleksic N, Rosamond WD, Tracy RP, Heckbert SR. Fibrin fragment D-Dimer and the risk for future venous thrombosis. Blood. 2003;101:1243-8.
25. De Loughery TG, Roberton DG, Smith CA, Sauer D. Moderate hypoxia suppresses exercise-induced procoagulant changes. Br J Haematol. 2004;125;369-72.
26. Cushman M. Response: Use of D-Dimer in thrombosis risk assessment. Blood. 2003;102:4618-9.
27. Sakkinen PA, Macy EM, Callas PW, Cornell ES, Hayes TE, Kuller LH, Tracy RP. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol. 1999;149:261-7.